The current stock price of HOTH is 0.95 USD. In the past month the price decreased by -10.38%. In the past year, price decreased by -15.93%.
ChartMill assigns a fundamental rating of 2 / 10 to HOTH. HOTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -131.58% | ||
| ROE | -147.77% | ||
| Debt/Equity | 0 |
7 analysts have analysed HOTH and the average price target is 5.1 USD. This implies a price increase of 436.84% is expected in the next year compared to the current price of 0.95.
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.54 | 987.61B | ||
| JNJ | JOHNSON & JOHNSON | 20.46 | 574.955B | ||
| MRK | MERCK & CO. INC. | 21.65 | 292.01B | ||
| PFE | PFIZER INC | 9.19 | 153.798B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10 | 123.713B | ||
| ZTS | ZOETIS INC | 18.66 | 56.1B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.52 | 25.427B | ||
| VTRS | VIATRIS INC | 6.31 | 17.921B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.5 | 12.337B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.04 | 9.236B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 2
Phone: 16467562997
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
The current stock price of HOTH is 0.95 USD. The price increased by 10.68% in the last trading session.
HOTH does not pay a dividend.
HOTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
HOTH THERAPEUTICS INC (HOTH) currently has 2 employees.